The use of amisulpride in the treatment of acute psychosis

Therapeutics and Clinical Risk Management

Volumn 3, Issue 1, 2007, Pages 3-11

  Nuss, Philippe ^a,c   Hummer, Martina ^b   Tessier, Cédric ^a  

^a SORBONNE UNIVERSITÉ   (France)

^b UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

^c HÔPITAL SAINT ANTOINE   (France)

Author keywords

Acute psychosis; Amisupride; Efficacy; Safety; Schizophrenia

Indexed keywords

ALPRAZOLAM; AMISULPRIDE; ANTIDEPRESSANT AGENT; ANTIPARKINSON AGENT; ANXIOLYTIC AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE DERIVATIVE; CLOZAPINE; DIAZEPAM; HALOPERIDOL; LORAZEPAM; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE;

ACUTE PSYCHOSIS; AGITATION; AMENORRHEA; ANXIETY; CLINICAL PROTOCOL; CLINICAL TRIAL; CONSTIPATION; DISTRESS SYNDROME; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG DISTRIBUTION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG INDUCED HEADACHE; DRUG MONITORING; DRUG TOLERANCE; DYSKINESIA; EJACULATION DISORDER; EMERGENCY WARD; EXTRAPYRAMIDAL SYMPTOM; EXTRAPYRAMIDAL SYNDROME; FATIGUE; GALACTORRHEA; HUMAN; HYPERKINESIA; IMPOTENCE; INSOMNIA; LOADING DRUG DOSE; META ANALYSIS; MUSCLE HYPERTONIA; NEGATIVE SYNDROME; NEUROIMAGING; OPTIMAL DRUG DOSE; POSITIVE SYNDROME; PRIMARY HEALTH CARE; PROLACTIN BLOOD LEVEL; PSYCHOSIS; REVIEW; RHINITIS; SCHIZOPHRENIA; SIDE EFFECT; SOMNOLENCE; SUBSTANCE ABUSE; SYMPTOMATOLOGY; SYSTEMATIC REVIEW; VOMITING; WEIGHT GAIN;

EID: 34247620248     PISSN: 11766336     EISSN: None     Source Type: Journal    
DOI: 10.2147/tcrm.2007.3.1.3     Document Type: Review

References (52)

1. Allen MH, Currier GW, Hughes DH, et al; Expert Consensus Panel for Behavioral Emergencies. 2001. The Expert Consensus Guideline Series. Treatment of behavioral emergencies. Postgrad Med, (Spec No):1-88
2. Barbee JG, Mancuso DM, Freed CR, et al. 1992. Alprazolam as a neuroleptic adjunct in the emergency treatment of schizophrenia. Am J Psychiatry, 149:506-10.
3. Battaglia J. 2005. Pharmacological management ofacute agitation. Drugs, 65:1207-22.
4. Battaglia J, Moss S, Rush J, et al. 1997. Haloperidol, lorazepam, or both for psychotic agitation? A multicenter, prospective, double-blind, emergency department study. Am J Emerg Med, 15:335-40.
5. Canal M, Gilet G, Simpson H. 2004. Lack of drug interaction potential of amisulpride P01-503. Int J Neuropsychopharmacology, 7:S265
6. Carrière P, Bonhomme D, Lempérière T. 2000. Amisulpride has a superior benefit/risk profile to haloperidol in schizophrenia: results of a multicentre, double-blind study (the Amisulpride Study Group). Eur Psychiatry, 15:321-9.
7. Chakos M, Lieberman J, Hoffman E, et al. 2001. Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. Am J Psychiatry, 158:518-26.
8. Colonna L, Saleem P, Dondey-Nouvel L, et al; Amisulpride Study Group. 2000. Long-term safety and efficacy of amisulpride in subchronic or chronic schizophrenia, Int Clin Psychopharmacol, 15:13-22.
9. Costa e Silva JA. 1989. Comparative double-blind study of amisulpride versus haloperidol in the treatment of acute psychotic states. Paris, France, Amisulpride, Expansion Scientifique Française, pp 93-104.
10. Coulouvrat C, Dondey-Nouvel L. 1999. Safety of amisulpride (Solian): a review of 11 clinical studies. Int Clin Psychopharmacol; 14:209-18
11. Currier GW, Medori R. 2006. Orally versus intramuscularly administered antipsychotic drugs in psychiatric emergencies. J Psychiatr Pract, 2:30-40.
12. Davis JM, Chen N, Glick ID. 2003. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry, 60:553-64.
13. Davis JM, Chen N. 2005. Old versus new: weighing the evidence between the first- and second-generation antipsychotics. Eur Psychiatry, 20:7-14.
14. Delcker A, Schoon ML, Oczkowski B, et al. 1990. Amisulpride versus haloperidol in treatment ofschizophrenic patients - results ofa double-blind study. Pharmacopsychiatry, 23:125-30.
15. Farde L, Nordstrom AL, Wiesel FA, et al. 1992. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine: relation to extrapyramidal side effects. Arch Gen Psychiatry, 49:538-44.
16. Foster S, Kessel J, Berman ME, et al. 1997. Efficacy of lorazepam and haloperidol for rapid tranquilization in a psychiatric emergency room setting. Int Clin Psychopharmacol, 12:175-9.
17. Geddes J, Freemantle N, Harrison P, et al. 2000. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. Br Med J, 321:1371-6.
18. Hwang TJ, Lee SM, Sun HJ, et al. 2003. Amisulpride versus risperidone in the treatment of schizophrenic patients: a double-blind pilot study in Taiwan. J Formos Med Assoc, 102:30-6.
19. Kemmler G, Hummer M, Widschwendter C, et al. 2005. Dropout rates in placebo-controlled and active-control clinical trials of antipsychotic drugs: a meta-analysis. Arch Gen Psychiatry, 62:1305-12.
20. Klein HE, Dieterle D, Wither E, et al. 1985. A double-blind comparison of amisulpride vs haloperidol in acute schizophrenic patients. Pichot P, Berner P, Wolf R, et al (eds). In Psychiatry: The State of the Art, vol 3: Pharmacopsychiatry. Cambridge, Mass, Perseus Books, pp 687-91.
21. Leucht S, Pitschel-Walz G, Abraham D, et al. 1999. Efficacy and extrapyramidal side-effects of the new atypical antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials, Schizophr Res, 35:51-68.
22. Leucht S, Pitschel-Walz G, Engel RR, et al. 2002. Amisulpride, an unusual "atypical" antipsychotic: a meta-analysis of randomized controlled trials. Am J Psychiatry, 159:180-90.
23. Martin S, Loo H, Peuskens J, et al. 2002. A double-blind, randomised comparative trial of amisulpride versus olanzapine in the treatment of schizophrenia: short-term results at two months. Curr Med Res Opin, 18:355-62.
24. Martinot JL, Paillere-Martinot ML, Poirier MF, et al. 1996. In vivo characteristics of dopamine D2 receptor occupancy by amisulpride in schizophrenia. Psychopharmacology (Berl), 124:154-8.
25. McKeage K, Plosker GL. 2004. Amisulpride: a review of its use in the management of schizophrenia. CNS Drugs, 18:933-56.
26. Möller HJ, Boyer P, Fleurot O, et al. 1997. Improvement of acute exacerbations of schizophrenia with amisulpride: a comparison with haloperidol, PROD-ASLP Study Group. Psychopharmacology, 132:396-401.
27. Müller MJ, Wetzel H, Eich FX, et al; Amisulpride Study Group. 2002. Dose-related effects of amisulpride on five dimensions of psychopathology in patients with acute exacerbation of schizophrenia. J Clin Psychopharmacol, 22:554-60.
28. Mortimer A, Martin S, Loo H, et al; for the SOLIANOL study group. 2004. A double-blind randomised comparative trial of amisulpride versus olanzapine for six months in the treatment of schizophrenia. Int Clin Psychopharmacol, 19:63-9.
29. Mota NE, Lima MS, Soares BG. 2002. Amisulpride for schizophrenia. Cochrane Database Syst Rev, 2: CD001357.
30. Naber D, Arlt J, Lambert M. 2003. Amisulpride: A safe and effective option for the long-term treatment of patients with schizophrenia. Int J Psych Clin Pract, 7:167-75.
31. NICE. 2002. Schizophrenia - atypical antipsychotics: The clinical effectiveness and cost effectiveness of newer atypical antipsychotic drugs for schizophrenia [online]. Accessed on 20 September 2006. URL: http://www.nice.org.uk/page.aspx?o=32878.
32. Overall JE, Gorham DR. 1962. The Brief Psychiatric Rating Scale. Psychol Reports, 10:799-812.
33. Perault MC, Bergougnan L, Paillat A, et al. 1998. Lack of interaction between amisulpride and lorazepam on psychomotor performance and memory in healthy volunteers. Hum Psychopharmacol, 13:493-500.
34. Perkins DO. 2002. Predictors of noncompliance in patients with schizophrenia. J Clin Psychiatry, 63:1121-8
35. Peuskens J, Bech P, Möller HJ, et al. 1999. Amisulpride vs. risperidone in the treatment of acute exacerbations of schizophrenia. Amisulpride study group. Psychiatry Res, 88:107-17.
36. Peuskens J, Moller HJ, Puech A. 2002. Amisulpride improves depressive symptoms in acute exacerbations of schizophrenia: comparison with halopcridol and risperidone. Eur Neuropsychopharmacol, 12:305-10.
37. Pichot P, Boyer P. 1988. Etude multicentrique controlde en double insu, amisulpride (Solian 200) versus halopéridol à forte dose dans les états psychotiques aigus. Annales de Psychiatrie, 3:326-32.
38. Puech A, Fleurot O, Rein W. 1998. Amisulpride, an atypical antipsychotic, in the treatment of acute episodes of schizophrenia: a dose-ranging study vs. haloperidol. The Amisulpride Study Group, Acta Psychiatr Scand, 98:65-72.
39. Reynolds GP. 1994. Antipsychotic drug mechanisms and neurotransmitter systems in schizophrenia. Acta Psychiatr Scand Suppl, 3 80:36-40.
40. Riedel M, Eich FX, M611er HJ; for the Amielderly group. 2005. A randomised, double-blind clinical trial comparing treatment with amisulpride or risperidone for six weeks in elderly patients with schizophrenia. Eur Neuropsychopharmacology, 15:S515.
41. Rosenzweig P, Canal M, Patat A, et al. 2002. A review of the pharmacokinetics, tolerability and pharmacodynamics of amisulpride in healthy volunteers. Hum Psychopharmacol, 17:1-13.
42. Rijther E, Blanke J. 1988. Therapievergleich von Ammosultoprid (DAN 2163) und Perazin bei schizophrenen Patienten, in Therapic mit Neuroleptika - Perazin. Helmchen H, Hippius H, Tölle R (eds). Stuttgart, Germany, Georg Thieme Verlag, p65-71.
43. Saletu B, Küfferle B, Gruenberger J, et al. 1994. Clinical, EEG mapping and psychometric studies in negative schizophrenia: comparative trials with amisulpride and fluphenazine. Pharmacopsychiatry, 29:125-35.
44. Sechter D, Peuskens J, Fleurot O, et al. 2002. Amisulpride vs. risperidone in chronic schizophrenia: results of a 6-month, double-blind study. Neuropsychopharmacology, 27:1071-81.
45. Simpson GM, Angus JW. 1970. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl, 212:11-19.
46. Speller JC, Barnes TRE, Curson DA, et al. 1997. One-year, low-dose neuroleptic study of in-patients with chronic schizophrenia characterised by persistent negative symptoms - amisulpride v haloperidol. Br J Psychiatry, 171:564-8.
47. Steinert T, Wiebe C, Gebhardt RP. 1999. Aggressive behavior against self and others among first-admission patients with schizophrenia. Psychiatr Serv, 50:85-90.
48. Storosum JG, Elferink AJ, van Zwieten BJ, et al. 2002. Amisulpride: is there a treatment for negative symptoms in schizophrenia patients? Schizophr Bull, 28:193-201.
49. Tamminga CA. 2003. The science of antipsychotics: mechanistic insight. CNS Spear, 8 (11 Suppl 2):5 -9.
50. Wetzel H, Grfinder G, Hillert A, et al. 1998. Amisulpride versus flupenthixol in schizophrenia with predominantly positive symptomatology - a double-blind controlled study comparing a selective D2-like antagonist to a mixed D1/D2-like antagonist. Psychopharmacology, 1137:223-32.
51. Wolkowitz OM, Pickar D. 1991. Benzodiazepines in the treatment of schizophrenia: a review and reappraisal. Am J Psychiatry, 148:714-26.
52. Ziegler B. 1989. Study of the efficacy of a substituted benzamide amisulpride, versus haloperidol, in productive schizophrenia, in Amisulpride. Paris, France, Expansion Scientifique Française, pp 73-82.